Professor Nicholas Barnes PhD

Professor Nicholas Barnes has been a member of the Faculty of the University of Birmingham Medical School since 1991 and holds the Chair in Neuropharmacology. He is Director of the Cellular and Molecular Neuropharmacology Research Group; the group’s principal research interest is 5-HT (5-hydroxytryptamine, serotonin). In addition, Professor Barnes is Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors. He is also Editor-in-Chief, Board Editor and Associate Editor for the international journals Frontiers in Neuropharmacology, Neuropharmacology, and Frontiers in Neuroscience, respectively. In addition to his academic-related positions, Professor Barnes is the Principal Founder and CEO of Celentyx Ltd; a venture capital funded pharmaceutical research and development company with a therapeutic focus on treating disorders of the immune system and targeting cancer treatment with immuno-oncology strategies.